Abstract:6082 Background: Despite adjuvant therapy, over 50% of surgically treated head and neck squamous cell carcinoma (HNSCC) patients (pts) experience a recurrence of disease. Systemic stimulation of cellular immunity against tumor mutations using a viral vaccine may be an ideal modality to clear residual cancer cells. For this purpose, we developed a pipeline for the design of TG4050, a personalized cancer vaccine (PCV) using a Modified Vaccinia Ankara (MVA) viral vector. We report here preliminary safety and immunogenicity data from a phase I TG4050 study. Methods: Surgically resected stage III or IV, HPV negative HNSCC pts were enrolled in the study. pts must have achieved clinical remission after adjuvant chemoradiotherapy. A PCV for each pt was manufactured with up to 30 neoantigens identified using a state-of-the-art machine learning algorithm, from next generation sequencing (NGS) data. Pts randomized to arm A received the PCV after completion of primary treatment. Pts randomized to arm B received the PCV in the event of relapse, in conjunction with second line therapy. The PCV schedule consisted of an induction period of 6 weekly administrations, followed by booster doses once every 3 weeks for up to one year. Immune cells were collected by leukapheresis at baseline and at day 64. Primary endpoint was safety. Secondary endpoints included feasibility, disease free survival and immune response as assessed by ex-vivo IFNg-ELISPOT. Results: At the time of data cut-off, a total of 31 pts were randomized, 15 in arm A and 16 in arm B. A vaccine was successfully designed for all randomized pts. Pts had no evidence of disease at baseline either at the clinical or molecular level, as assessed by ctDNA assessment. All adverse events (AEs) were mild to moderate and most were injection site reactions. Median follow-up was 9.2 months in arm A vs 7.6 months in arm B. None of the pts in arm A experienced relapse vs. 2 in the arm B. Immune monitoring demonstrated priming of a polyepitopic T cell response against the PCV in 100% of pts in arm A, among pts evaluated to date, with a mean of 9 responses per pt (6-19). Responses were observed regardless of HLA genotype, and without cross-reactivity to the wildtype antigen. Baseline tumor analyses revealed challenging genomic and immune profiles such as low TMB (avg of 3.06 ± 0.86 Mut/Mb), a majority of immune-desert tumors, and a low expression of important immune related factors including PD-L1 (16 pts out of 17 had a negative to moderate PD-L1 expression). Conclusions: Our preliminary data demonstrate that TG4050 is safe, well tolerated, and capable of inducing T cell responses in cold tumors. In summary viral based, PCVs designed to induce tumor-specific neoantigen may be associated with a safe tolerance and an improved outcome in HNSCC pts. Clinical trial information: NCT04183166 .

Supplementary figures 1-7 from Customized Viral Immunotherapy for HPV-Associated Cancer

Customized Viral Immunotherapy for HPV-Associated Cancer

Supplementary Figure 3 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell–Mediated Tumor Control in the Genital Tract

Preclinical Immunogenicity and Efficacy Studies for Therapeutic Vaccines for Human Papillomavirus-Type-16-Associated Cancer

Vaccination of Full-Length HPV16 E6 or E7 Protein Inhibits the Growth of HPV16 Associated Tumors

Supplementary Data from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment During Chemoradiotherapy is Prognostic in HPV16+ Cancers

Supplemental Table Legends from Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment During Chemoradiotherapy is Prognostic in HPV16+ Cancers

A Therapeutic DNA Vaccine Targeting HPV16 E7 in Combination with Anti-PD-1/PD-L1 Enhanced Tumor Regression and Cytotoxic Immune Responses

Immunoinformatics Design and In Vivo Immunogenicity Evaluation of a Conserved CTL Multi-Epitope Vaccine Targeting HPV16 E5, E6, and E7 Proteins

Differential tumor immune microenvironment coupled with tumor progression or tumor eradication in HPV-antigen expressing squamous cell carcinoma (SCC) models

Enhanced Immunotherapeutic Effect of Modified HPV16 E7-pulsed Dendritic Cell Vaccine by an Adeno-Shrna-socs1 Virus

Immunization of Protein HPV16 E7 in Fusion with Mouse HSP70 Inhibits the Growth of TC-1 Cells in Tumor Bearing Mice.

Supplementary Figures 1-2, Table 1 from Cancer Stem Cell Vaccination Confers Significant Antitumor Immunity

Supplementary Figure 5 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8<sup>+</sup> T-cell–Mediated Tumor Control in the Genital Tract

Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine

Fungal Mannosylation Enhances Human Papillomavirus 16 E7 Therapeutic Immunity Against TC-1 Tumors.

Identification of HPV-E7 specific TCRs for tumor immunotherapy

Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma.

Human HSP70 and Modified HPV16 E7 Fusion DNA Vaccine Induces Enhanced Specific CD8+ T Cell Responses and Anti-Tumor Effects.

Linkage of Modified Human Papillomavirus Type 16 E7 to CD40 Ligand Enhances Specific CD8 + T-lymphocyte Induction and Anti-tumour Activity of DNA Vaccine

Cervical Cancer-Associated Human Papillomavirus 16 E7 Oncoprotein Inhibits Induction of Anti-Cancer Immunity by a CD4+ T Cell Dependent Mechanism